Stocktoria
ORTHOPEDIATRICS CORP KIDS
ORTHOPEDIATRICS CORP (KIDS) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.14% (safety: no dividend). FY2025 revenue was $236.3M at a -16.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.66 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.413 |
| Retained earnings / assets | -0.541 |
| EBIT / assets | -0.077 |
| Equity / liabilities | 2.139 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| KIDS | ORTHOPEDIATRICS CORP | 4/9 | 2.67 | — | +15.4% |
| CERS | CERUS CORP | 4/9 | -13.54 | — | +16.1% |
| LMAT | LEMAITRE VASCULAR INC | 6/9 | 8.18 | 37.9 | +13.5% |
| TMCI | TREACE MEDICAL CONCEPTS, INC. | 2/9 | -1.79 | — | +1.6% |
| SIBN | SI-BONE, Inc. | 6/9 | 1.52 | — | +20.2% |
| HTFL | Heartflow, Inc. | 4/9 | -2.45 | — | +39.9% |
| SKIN | SkinHealth Systems Inc. | 6/9 | -1.89 | — | -10% |
About ORTHOPEDIATRICS CORP
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
FAQ
Is KIDS financially healthy?
ORTHOPEDIATRICS CORP's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does KIDS pay a dividend, and is it safe?
Yes. ORTHOPEDIATRICS CORP pays a dividend yielding about 1.14% with a None payout ratio, rated “no dividend” for safety.
How profitable is KIDS?
In FY2025, ORTHOPEDIATRICS CORP had a net margin of -16.8% and a return on equity of -11.4%.
What is the analyst price target for KIDS?
The average Wall-Street price target for ORTHOPEDIATRICS CORP is $24.67, about 0.8% below the recent price, from 9 analysts.
Is KIDS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ORTHOPEDIATRICS CORP: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone, a dividend yield of 1.14%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.